6.3 Packaging, Container-Closure Systems, Storage, and Quality Assurance

6.3 Packaging, Container-Closure Systems, Storage, and Quality Assurance

The final stages of nonsterile compounding—packaging, labeling, storage assignment, and quality control verification—are critical for ensuring that a compounded nonsterile preparation (CNSP) maintains its strength, quality, and purity throughout its intended shelf life. A formulation compounded with total accuracy will quickly degrade if packaged in an incompatible container, exposed to light or temperature extremes, or assigned an improper Beyond-Use Date (BUD). For pharmacy technicians preparing for the PTCB Nonsterile Compounding Certificate, mastering container classifications under USP <659>, storage temperature parameters, BUD calculation rules, physical inspection protocols, and Quality Assurance frameworks under USP <1163> is essential.

---

Container-Closure Systems and Packaging Science (USP <659>)

A container-closure system consists of the primary container (which holds the drug formulation in direct contact), the closure (cap, stopper, or seal), and any secondary packaging (outer boxes or light-shielding wraps). USP Chapter <659> (Packaging and Storage Requirements) establishes official definitions for pharmaceutical containers:

Container Classifications under USP <659>

• Well-Closed Container: Protects the contents from extraneous solids and from loss of the drug under ordinary conditions of handling, shipment, storage, and distribution.
• Tight Container: Protects the contents from contamination by extraneous liquids, solids, or vapors; prevents loss of the drug; and resists efflorescence, deliquescence, or evaporation under ordinary handling. USP <795> requires tight containers for all CNSPs to maintain stability.
• Hermetic Container: Impervious to air or any other gas under ordinary conditions of handling and storage.
• Light-Resistant Container: Protects the contents from the effects of light by virtue of the specific properties of the material of which it is composed (e.g., amber glass or amber High-Density Polyethylene [HDPE]). USP standards mandate that light-resistant containers must attenuate light transmission in the spectrum between 290 nm and 450 nm to prevent photodegradation of light-sensitive active pharmaceutical ingredients (APIs) such as furosemide, nifedipine, or hydrocortisone.

Material Compatibility and Selection Guidelines

Selecting the proper container material requires evaluating physical and chemical interactions between the formulation and the packaging matrix:

Child-Resistant Packaging Requirements

Under the Poison Prevention Packaging Act (PPPA) of 1970, most oral compounded prescription preparations dispensed for outpatient use must be packaged in child-resistant closures (CRCs) unless the prescriber or patient explicitly requests non-child-resistant packaging, or the specific drug category is exempt by law.

---

Storage Temperature Standards and Environmental Monitoring

Drug stability is directly influenced by storage temperature. USP Chapter <659> defines standard temperature ranges for pharmaceutical storage:

Temperature Monitoring Protocols

Facilities monitor storage conditions at a frequency and by a method capable of detecting relevant excursions, based on labeled conditions, risk, device instructions, SOPs, and applicable law. Continuous data loggers are useful but are not universally mandated by USP <795>. Investigate excursions, quarantine affected items when quality is uncertain, and document disposition.

---

Comprehensive Labeling Requirements for Nonsterile Compounds

Labels for compounded nonsterile preparations must contain explicit information to guide safe patient administration and comply with federal and state regulations. Standard labeling elements include:

1. Patient Identification: Full legal name of the patient (or animal owner and species);
2. Prescriber Name: Name of the ordering licensed healthcare practitioner;
3. Pharmacy Details: Name, address, and telephone number of the compounding pharmacy;
4. Internal Identifier: Unique prescription number and internal compounding lot number;
5. Active Ingredient Details: Established names, active strength, and total volume or quantity dispensed;
6. Assigned Beyond-Use Date (BUD): Specific date (and time, if applicable) beyond which the preparation must not be used;
7. Directions for Use: Clear dosage instructions and route of administration;
8. Storage Instructions: Explicit storage conditions (e.g., "Keep Refrigerated at 2°C to 8°C");
9. Auxiliary Warning Labels: Required cautionary statements such as:
   • "Shake Well Before Use" (for suspensions);
   • "For External Use Only" (for topical creams, ointments, lotions);
   • "Keep Out of Reach of Children";
   • "Compounded Preparation" disclaimer.

---

Beyond-Use Date (BUD) Calculation Logic and Worked Mathematics

Assigning a correct Beyond-Use Date is one of the most critical quality control responsibilities in compounding. Under USP Chapter <795>, default BUDs are determined based on water activity (a_w), formulation type, and storage temperature, in the absence of published stability-indicating analytical studies.

General Governing Rule for BUDs

Assigned BUD = Minimum ( USP <795> Default Matrix Limit, Shortest Ingredient Expiration Date, Published Stability Limit )

THE CARDINAL RULE: An assigned BUD can NEVER extend past the shortest expiration date of any individual active pharmaceutical ingredient (API) or raw excipient used to compound the preparation!

USP <795> Default BUD Summary Matrix

• Nonaqueous oral liquids: 90 days at controlled room temperature or refrigerated.
• Other nonaqueous dosage forms: 180 days at controlled room temperature or refrigerated.
• Nonpreserved aqueous dosage forms: 14 days refrigerated.
• Preserved aqueous dosage forms: 35 days at controlled room temperature or refrigerated.

---

Worked Calculation Examples

Example 1: Nonaqueous Progesterone Capsules

• Compounding Date: August 1, 2026
• Formulation: Nonaqueous powder blend in hard gelatin capsules.
• Ingredient Expiration Dates:
  • Progesterone API powder: Expiration date = December 15, 2026 (136 days away)
  • Microcrystalline Cellulose filler: Expiration date = October 30, 2027 (455 days away)
  • Lactose Monohydrate filler: Expiration date = June 1, 2028 (670 days away)
• Calculation:
  • USP <795> default limit for nonaqueous forms = 180 days (which would be January 28, 2027).
  • Shortest ingredient expiration date = Progesterone API expiring on December 15, 2026 (136 days).
• Final Assigned BUD: December 15, 2026 (capped by the shortest ingredient expiration date).

Example 2: Water-Containing Oral Omeprazole Suspension

• Compounding Date: August 1, 2026
• Formulation: Nonpreserved aqueous oral suspension stored in a refrigerator.
• Ingredient Expiration Dates:
  • Omeprazole raw powder: Expiration date = November 20, 2027
  • Sodium Bicarbonate vehicle: Expiration date = January 10, 2028
• Calculation:
  • USP <795> default for a nonpreserved aqueous dosage form stored at 2°C to 8°C = 14 Days.
  • 14 days from August 1, 2026 = August 15, 2026.
  • Shortest ingredient expiration is over a year away.
• Final Assigned BUD: August 15, 2026 (Refrigerated).

Example 3: Minimum Weighable Quantity (MWQ) Review

A technician needs to weigh an active drug on a Class III prescription balance with a Sensitivity Requirement (SR) of 6 mg, accepting a maximum allowable error of 5% (0.05).

• Formula: MWQ = SR / 0.05
• Calculation: MWQ = 6 mg / 0.05 = 120 mg
• Conclusion: The minimum quantity of drug that can be accurately weighed on this balance is 120 mg.

Example 4: Percentage Error Verification

A technician targets 200 mg of powder, but the actual balance reading is 206 mg.

• Formula: Percentage Error = ( | Target Weight - Actual Weight | / Target Weight ) * 100%
• Calculation: Percentage Error = ( | 200 mg - 206 mg | / 200 mg ) * 100% = ( 6 mg / 200 mg ) * 100% = 3%
• Conclusion: The 3% error is within the acceptable +/- 5% tolerance limit.

---

Quality Assurance (QA) and Quality Control (QC) under USP <1163>

USP Chapter <1163> (Quality Assurance in Pharmaceutical Compounding) describes the administrative and analytical checks required to ensure consistent compound quality.

Core QA/QC Documentation

• Master Formulation Record (MFR): The master "recipe" created prior to compounding. Contains official compound name, dosage form, strength, complete list of ingredients with exact quantities, step-by-step compounding instructions, equipment needed, packaging/container specifications, storage requirements, and calculation algorithms.
• Compounding Record (CR): The batch-specific execution log filled out during compounding. Documents the specific brand, manufacturer, lot numbers, and expiration dates of raw materials used, actual measured weights/volumes, technician signature, verifying pharmacist signature, unique prescription lot number, and final assigned BUD.

Physical Inspection and Quality Checks

Before release, authorized personnel perform the checks defined by the master formulation, facility SOP, applicable monograph, and jurisdiction. Technicians may collect or document results within their permitted role; final release authority follows law and policy.

1. Weight/Uniformity Testing: For capsules, use the approved sampling plan and acceptance criteria. A 10-unit ±10% rule is not universal across all formulations.
2. Visual Inspection: Check oral liquids for un-dispersed clumps or precipitation; check creams for phase separation (oil splitting from water); check capsules for physical denting or incomplete closure.
3. Organoleptic & pH Testing: Measure pH using a calibrated digital pH meter to ensure formulation falls within the target stability pH window.

Handling Out-of-Specification (OOS) Results

If a compounded batch fails quality control checks (e.g., pH outside limit, weight variation exceeds tolerance, or visual phase separation occurs):

• The batch must be immediately quarantined and flagged as Out-of-Specification (OOS);
• The batch must never be dispensed to a patient;
• A formal root-cause investigation must be documented to determine whether calculation errors, raw material failure, or equipment malfunction occurred;
• Corrective Action and Preventive Action (CAPA) plans must be executed and logged.